-
Agios Pharmaceuticals Inc. NASDAQ:AGIO Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.
Location: 88 Sidney St, Massachusetts, 02139-4137, US | Website: www.agios.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.077B
Cash
569.9M
Avg Qtr Burn
-76.65M
Short % of Float
6.50%
Insider Ownership
1.55%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tibsovo (Ivosidenib) (IDH1m inhibitor) Details AML (Acute Myeloid Leukemia) | Approved Quarterly sales | |
VORANIGO (Vorasidenib) Details Glioma, Brain tumor | Approved Quarterly sales | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Sickle cell disease, Anemia | Approved Quarterly sales | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Beta thalessemia | sNDA Submission | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Anemia, Sickle cell disease | Phase 3 Data readout | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Pyruvate Kinase Deficiency | Phase 3 Data readout | |
AG-946 Details Myelodysplastic syndrome | Phase 2b Initiation | |
AG-181 Details Phenylketonuria | Phase 1 Data readout |